Research record / starter review

Retatrutide

Investigational triple hormone-receptor agonist

Medical trial contextLast reviewed 2026-07-13

Also called

LY3437943 · GIP/GLP-1/glucagon triple agonist

What people ask about

Community claims

body-composition claimsweight-loss claimsmetabolic-health claims

These are topics circulating in appearance, physique, or recovery communities. Listing them does not validate them.

What this record can say

Evidence snapshot

A 2026 phase-III study in adults with type-2 diabetes reported body-weight and glycaemic outcomes over 40 weeks. This is clinical evidence in a defined medical population, not an individual recommendation or evidence for general appearance goals.

Safety context

Read uncertainty as information

A clinical-trial report is not a substitute for individual medical assessment, regulator review, or long-term post-marketing safety evidence. This library does not provide a use plan.

Tested sport

Anti-doping context

No simplified clearance label is shown. Tested athletes should verify the current Prohibited List with their anti-doping organisation before relying on any status.

Regulatory scope

Context is not a universal answer

This record reports a published clinical-development study and does not make a global authorisation or legal-status determination.

Study-level evidence

What the individual records actually say.

Every row preserves identity and context. A related molecule, a tissue experiment, or a trial registration cannot become proof for the community claim.

Published phase-III randomised, double-blind, placebo-controlled trial2026

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1) ↗

Bajaj HS, et al. Lancet. 2026. PMID: 42250575. DOI: 10.1016/S0140-6736(26)00967-0.

Identity: Exact compound name: retatrutide

Design & population: 40-week, phase-III, randomised, double-blind, placebo-controlled trial in 537 adults with type-2 diabetes and inadequate glycaemic control at 48 sites.

Question studied: Glycaemic control, body-weight change, and trial-period safety in adults with type-2 diabetes.

Record finding: The paper reports statistically significant differences from placebo in glycated haemoglobin and body-weight outcomes for the trial regimens studied.

Does not show: It does not establish an appropriate use, eligibility, long-term safety, or expected outcome for a person without the study population's medical context. It is not an appearance or lookmaxxing study.

Direct human phase-III evidence — condition-specific clinical populationChecked 2026-07-13

Primary sources

Read the source, not only our summary.

bibliographic index / primary paper linksPubMedU.S. National Library of Medicine ↗anti-doping2026 Prohibited ListWorld Anti-Doping Agency ↗